SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics

References

• BADGER, A. M., GRISWOLD, D. E., KAPADIA, R., BLAKE, S., SWIFT, B. A., HOFFMAN, S. J., STROUP, G. B., WEBB, E., RIEMAN, D. J., GOWEN, M., BOEHM, J. C., ADAMS, J. L. and LEE, J. C., 2000, Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced disease. Arthritis Rheumatism, 43, 175–183.
   PubMed Web of Science ®Google Scholar
• BENET, L. Z., MITCHELL, J. R. and SHEINER, L. B., 1990, Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In A. G. Gilman, T. W. Rail, A. S. Nies and P. Taylor (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics (New York: Pergamon), pp. 3–32.
   Google Scholar
• BONATE, P. L., REITH, K. and WEIR, S., 1998, Drug interactions at the renal level: implications for drug development. Clinical Pharmacokinetics, 34, 375–404.
   PubMed Web of Science ®Google Scholar
• COBB, M. H., 1999, MAP kinase pathways. Progress in Biophysics and Molecular Biology, 71, 479–500.
   PubMed Web of Science ®Google Scholar
• CUENDA, A., ROUSE, J., DOZA, Y. N., MEIER, R., COHEN, P., GALLAGHER, T. F., YOUNG, P. R. and LEE, J. C., 1995, SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Letters, 364, 229–233.
   PubMed Web of Science ®Google Scholar
• FRESHNEY, N. W., RAWLINSON, L., GUESDON, F., JoNEs, E., COWLEY, S., HSUAN, J. and SAKLATVALA, J., 1994, Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell, 78, 1039–1049.
   PubMed Web of Science ®Google Scholar
• FULLERTON, T., SHARMA, A., PRABHAKAR, U., Tucci, M., BOIKE, S. and Davis, H., 2000, Suppression of ex vivo cytokine production by SB 242235, a selective inhibitor of p38 MAP kinase. Clinical Pharmacology and Therapeutics, 114 (Meeting Abstract).
   Google Scholar
• GABRIELSSON, J. and WEINER, D., 1997, Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications (Stockholm: Apotekarsocieteten).
   Google Scholar
• HAN, J., LEE, J.-D., BIBBS, L. and ULEVITCH, R. J., 1994, A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science, 265, 808–811.
   Google Scholar
• HINDERLING, P. H., 1997, Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacology Reviews, 49, 279–295.
   PubMed Web of Science ®Google Scholar
• LEE, J. C., BADGER, A. M., GRISWOLD, D. E., DUNNINGTON, D., TRUNEH, A., VOTTA, B., WHITE, J. R., YOUNG, P. R. and BENDER, P. E., 1993, Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Annals of the New York Academy of Sciences, 696, 149–170.
   PubMed Web of Science ®Google Scholar
• LEE, J. C., LAYDON, J. T., MCDONNELL, P. C., GALLAGHER, T. F., KUMAR, S., GREEN, D., MCNULTY, D., BLUMENTHAL, M. J., HEYS, J. R., LANDVATTER, S. W., STRICKLER, J. E., MCLAUGHLIN, M. M., SIEMENS, I. R., FISHER, S. M., LIVI, G. P., WHITE, J. R., ADAMS, J. L. and YOUNG, P. R., 1994, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 372, 739–746.
   PubMed Web of Science ®Google Scholar
• NEWTON, J. F., YODIS, L. P., KEOHANE, D., ECKARDT, R., DEWEY, R., DENT, J. and Mico, B., 1989, Pharmacokinetics and metabolism of SK&F 86002 in male and female Sprague—Dawley rats. Drug Metabolism and Disposition, 17, 174–179.
   PubMed Web of Science ®Google Scholar
• PACIFICI, G. M. and VIANI, A., 1992, Methods of determining plasma and tissue binding of drugs. Clinical Pharmacokinetics, 23, 449–468.
   PubMed Web of Science ®Google Scholar
• ROUSE, J., COHEN, P., TRIGON, S., MORANGE, M., ALONSO-LLAMAZARES, A., ZAMANILLO, D., HUNT, T. and NEBREDA, A. R., 1994, A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell, 78, 1027–1037.
   PubMed Web of Science ®Google Scholar
• STEIN, B. and ANDERSON, D., 1996, The MAP kinase family: new `MAPs' for signal transduction pathways and novel targets for drug discovery. Annals in the Reporting of Medical Chemistry, 31, 289–298.
   Web of Science ®Google Scholar
• UNDERWOOD, D. C., OSBORN, R. R., KOTZER, C. J., ADAMS, J. L., LEE, J. C., WEBB, E. F., CARPENTER, D. C., BOCHNOWICZ, S., THOMAS, H. C., HAY, D. W. P. and GRISWOLD, D. E., 2000, SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Journal of Pharmacology and Experimental Therapeutics, 293, 281–288.
   Google Scholar
• WARD, K. W., GRIFFITHS, R., LEVY, M. A. and SMITH, B. R., 2000, Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity. Journal of Pharmacology and Experimental Therapeutics, 293, 468–479.
   PubMed Web of Science ®Google Scholar
• WARD, K. W., PROKSCH, J. W., GORYCKI, P. D., Yu, C.-P., Ho, M. Y. K., BUSH, B. D., LEVY, M. A. and SMITH, B. R., 2002, SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II. In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man. Xenobiotica, 32, 235–250.
   Google Scholar
• Yu, R., MANDELKAR, S., LEI, W., FAHL, W. E., TAN, T.-H. and KONG, A.-N. T., 2000, p38 mitogen-activated protein kinase negatively regulates the induction of Phase II drug-metabolizing enzymes that detoxify carcinogens. Journal of Biological Chemistry, 275, 2322–2327.
   Google Scholar